FDA OKs MiddleBrook's Moxatag

01/25/2008 | Washington Post, The

The FDA has approved MiddleBrook Pharmaceuticals' once-daily amoxicillin candidate Moxatag for treating strep throat in adolescents and adults, the company announced Thursday. Moxatag, which was developed using MiddleBrook's Pulsys time-release technology, is expected on the market in the last quarter of the year.

View Full Article in:

Washington Post, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations